ES2118941T3 - Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta. - Google Patents

Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta.

Info

Publication number
ES2118941T3
ES2118941T3 ES93906084T ES93906084T ES2118941T3 ES 2118941 T3 ES2118941 T3 ES 2118941T3 ES 93906084 T ES93906084 T ES 93906084T ES 93906084 T ES93906084 T ES 93906084T ES 2118941 T3 ES2118941 T3 ES 2118941T3
Authority
ES
Spain
Prior art keywords
compositions
carbonic
anhidrase
topics
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906084T
Other languages
English (en)
Inventor
Thomas Robert Dean
Louis Desantis Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Application granted granted Critical
Publication of ES2118941T3 publication Critical patent/ES2118941T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACEUTICAS OFTALMICAS, UTILES PARA CONTROLAR LA ELEVADA PRESION INTRAOCULAR, RELACIONADA CON EL GLAUCOMA Y LA HIPERTENSION OCULAR. LAS COMPOSICIONES COMPRENDEN UNA COMBINACION DE UN INACTIVADOR BETA Y UN INHIBIDOR DE ANHIDRASA CARBONICA, PARA REDUCIR LA PRODUCCION DE HUMOR ACUOSO, PREFERENTEMENTE FORMULADO COMO UNA SUSPENSION QUE TIENE UN PH ENTRE UN 6''8 Y UN 7''8. ESTAS COMPOSICIONES PUEDEN CONTENER ADICIONALMENTE UN POLIMERO ANIONICO MUCOMIMETICO Y/O UN SUSTRATO PORTADOR DE UN MEDICAMENTE FINAMENTE DIVIDIDO, PARA PROPORCIONAR LIBERACION SOSTENIDA. TAMBIEN SE DESCRIBE UN METODO PARA CONTROLAR LA PRESION INTRAOCULAR ELEVADA CON ESTAS COMPOSICIONES.
ES93906084T 1992-02-21 1993-02-19 Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta. Expired - Lifetime ES2118941T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83986992A 1992-02-21 1992-02-21

Publications (1)

Publication Number Publication Date
ES2118941T3 true ES2118941T3 (es) 1998-10-01

Family

ID=25280847

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906084T Expired - Lifetime ES2118941T3 (es) 1992-02-21 1993-02-19 Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta.

Country Status (9)

Country Link
EP (1) EP0625903B1 (es)
JP (2) JP2965267B2 (es)
AT (1) ATE169499T1 (es)
AU (1) AU677577B2 (es)
CA (1) CA2129037C (es)
DE (1) DE69320329T2 (es)
DK (1) DK0625903T3 (es)
ES (1) ES2118941T3 (es)
WO (1) WO1993016701A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
CA2294343A1 (en) * 1997-06-26 1999-01-07 Merck & Co., Inc. Method for optimizing retinal and optic nerve health
CA2317121A1 (en) * 1998-01-23 1999-07-29 Merck Sharp & Dohme B.V. Carbonic anhydrase inhibitor for increasing oxygen tension in the optic nerve and retina
AU5251999A (en) * 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
WO2015031109A1 (en) * 2013-08-28 2015-03-05 University Of Pittsburgh-Of The Common Wealth System Of Higher Education Inhibition of wnt, tgf beta and hippo signaling pathways to treat cancer, organ fibrosis and metabolic disorders
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス， インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655663A (en) 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
DE3568431D1 (en) * 1984-12-12 1989-04-06 Merck & Co Inc Substituted aromatic sulfonamides, their preparation and ophthalmic compositions containing them
US4863922A (en) * 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
US4731368A (en) * 1986-12-08 1988-03-15 Merck & Co., Inc. Thienopyridine sulfonamides and their ophthalmological formulation
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
EP0309028A3 (en) * 1987-09-16 1990-06-27 Merck & Co. Inc. Substituted thieno(2,3-b)furan-2-sulfonamides as antiglaucoma agents
US4946859A (en) * 1989-07-31 1990-08-07 Merck & Co., Inc. 4-(2-methyl-2-hydroxypropylamino)-5,6-dihydrothieno-[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide
US5153192A (en) * 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
IE911192A1 (en) * 1990-04-12 1991-10-23 Merck & Co Inc Substituted aromatic sulfonamides as antiglaucoma agents
DK0495421T3 (da) * 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
CA2064160C (en) * 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
CZ285129B6 (cs) * 1991-04-17 1999-05-12 Merck & Co., Inc. Oftalmické přípravky, obsahující kombinace inhibitoru karboanhydrasy a beta-adrenergního antagonisty

Also Published As

Publication number Publication date
WO1993016701A2 (en) 1993-09-02
WO1993016701A3 (en) 1994-01-06
CA2129037C (en) 1998-03-24
AU3725793A (en) 1993-09-13
JPH07504899A (ja) 1995-06-01
JP2965267B2 (ja) 1999-10-18
DE69320329D1 (de) 1998-09-17
EP0625903B1 (en) 1998-08-12
AU677577B2 (en) 1997-05-01
DK0625903T3 (da) 1999-05-10
EP0625903A1 (en) 1994-11-30
ATE169499T1 (de) 1998-08-15
HK1009941A1 (en) 1999-06-11
DE69320329T2 (de) 1998-12-24
CA2129037A1 (en) 1993-09-02
JPH10324640A (ja) 1998-12-08

Similar Documents

Publication Publication Date Title
AU1387088A (en) Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocularpressure
PT639563E (pt) Utilizacao de ester de isopropilo de fluprostenol para a producao de um medicamento para o tratamento do glaucoma e hipertensao ocular
EP0308021A3 (en) Subsituted thieno (2,3-b)pyrole-5-sulfonamides as antiglaucoma agents
FI902258A0 (fi) Menetelmä farmakologisesti aktiivisten 13,14-dihydro-17-fenyyli-18,19,20-trinor-PGF2 -alkyyliestereiden valmistamiseksi
DE69422707D1 (de) Verfahren zur verhinderung der trübung der hinteren linsenkapsel
IE811654L (en) Ophthalmic composition
AU1838788A (en) Substituted aromatic sulfonamides as antiglaucoma agents
ATE169499T1 (de) Topische antiglaukoma zusammensetzungen, enthaltend karbonhydrasehemmer und beta-blocker
AU1745388A (en) Thiophene sulfonamide antiglaucoma agents
BR9307099A (pt) Formulação de colírio processo para preparar uma formulação de colírio e processo de tratamento de hipertensão ocular e glaucoma
WO1992000287A3 (en) Analogs of carbonic anhydrase inhibitors and their use as topical iop inhibitors
ATE117208T1 (de) Behandlung von intraokularem druck mit einer ophthalmischen synergistischen kombination.
DE3886314D1 (de) Substituierte Thieno(2,3-b) thiophen-2-sulfonamide als Mittel gegen Glaukoma.
EP0122178A3 (en) Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
DK645489A (da) Antiglaukompraeparater indeholdende kombinationer af sympatomimetiske midler og beta-1 selektive beta-blokkere
ID22073A (id) Turunan-turunan nitrometil tiobenzena sebagai bahan penghambat aldosa reduktase
EP0527748A4 (en) Use of prostaglandin f 3 alpha as an ocular hypotensive agent
EP0309028A3 (en) Substituted thieno(2,3-b)furan-2-sulfonamides as antiglaucoma agents

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625903

Country of ref document: ES